News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
James Davis: Dexamethasone for CRS with teclistamab in R/R Multiple Myeloma
James Davis/X
Mar 5, 2025, 12:14

James Davis: Dexamethasone for CRS with teclistamab in R/R Multiple Myeloma

James Davis, Assistant professor and malignant hematology pharmacist at MUSC Hollings Cancer Center, shared an article he and his colleagues authored on X:

“Hot off the press!

Dexamethasone for CRS with teclistamab. You don’t need toci for grade 1 CRS! great team work.”

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma

Authors: James Davis et al.

multiple myeloma

 

Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, reshared the post on X, adding:

“Congrats James Davis et al for great Blood Cancer Journal work!

Consider prescribing “pocket dex” for patients following Multiple Myeloma bsAbs. 10mg for Gr1 CRS after ing with team. Easier for pts, easier for centers, works well, and much cheaper than toci!”

Charlotte B. Wagner Christopher Cahoon Donald C. Moore Grace Elsey Hailey Hill Jack Khouri James A. Davis James Davis Jessica McElwee Jordan Snyder Joslyn Rudoni Katelynn Granger Kelley Julian Kimberly M. Green Mikhaila Rice Shebli Atrash Victoria R. Nachar Zahra Mahmoudjafari
Special Coverage
Career
Apr 24, 2025, 21:39
Triparna Sen: I am thrilled and humbled to be nominated as a candidate for the IASLC Board of Directors
Blog
Apr 24, 2025, 21:05
Liz O’Riordan: 25 things I wish I had known before I got breast cancer
Blog
Apr 24, 2025, 20:53
Signing Ceremony of MoU Between Doha University for Science and Technology and Qatar Cancer Society
Blog
Apr 24, 2025, 20:40
Yan Leyfman: How AI is transforming cancer care - from improving diagnosis to reducing disparities
Insight
Apr 24, 2025, 20:28
Fernando Campos: We revealed a harsh Brazilian reality in Sarcoma Study
Insight
Apr 24, 2025, 19:38
George Vlachogiannis: Black patients were less likely to receive nephrectomy compared to non-Hispanic White patients
Blog
Apr 24, 2025, 18:30
Paolo Tarantino: Recent ADCs took a median time of 7 years from clinical introduction to approval
Blog
Apr 24, 2025, 17:56
Milestones from Philippine Cervical Cancer Elimination Operational Plan Workshop - APAC Women's Cancer Coalition
Blog
Apr 24, 2025, 17:55
Julie S. Torode: Attending my first ever AACR conference this week - long over due
Blog
Apr 24, 2025, 17:41
The Ohio State’s James Cancer Hospital and Solove Research Institute Welcomes Dr. Kimryn Rathmell as New CEO
Blog
Apr 24, 2025, 17:36
Bishal Gyawali: WHO EML working group discussion on checkpoint inhibitors for solid cancers
Blog
Apr 24, 2025, 17:27
Shane Jacobson: I had the chance to celebrate Dave Coulier being cancer free and now an Ambassador for the V Foundation